Monthly Archives: March 2010

Cato Sponsors BayBio 2010 Conference

Posted on 31 March 2010 by Evan Richardson

BayBio will be holding it’s annual conference, BayBio 2010, on Wednesday, 07 April 2010 at the Hyatt Regency San Francisco Airport in Burlingame, California.  This year’s conference will examine the fundamental questions of who pays for biotech innovation and why … Continue reading →

Posted in Conferences and Meetings | Tagged , , , , , , | Comments Off

Cato at MAGI’s Clinical Research Conference – 2010 East

Posted on 30 March 2010 by Evan Richardson

The MAGI Clinical Research Conference – 2010 East (MAGI2010E) will be held from 23-26 May 2010 at the Sheraton Boston Hotel in Boston, Massachusetts.  The conference will feature over 150 speakers and 92 sessions and workshops in six tracks: sponsor … Continue reading →

Posted in Conferences and Meetings | Tagged , , , , | Comments Off

Download the Slides from the Authoring Best Practices Webinar

Posted on 29 March 2010 by Evan Richardson

The slides from last Thursday’s webinar with GlobalSubmit on Document Authoring Best Practices for eCTD Submissions are available for download here (PDF file). Thanks to all of you who attended the webinar.  As always, we had a great group in … Continue reading →

Posted in eCTD, Webinars | Tagged , , , , | Comments Off

Biotech Wins Protection From Biosimilars

Posted on 25 March 2010 by Leo DiNapoli

Love is the power to see similarity in the dissimilar. – Theodor Adorno When President Obama signed the healthcare reform legislation into law, he also handed a major victory to biotech companies. Unless you’ve been stranded on a deserted island … Continue reading →

Posted in Industry News | Tagged , , , , , , , | 1 Comment

Challenges associated with oncology development within an immunotherapeutic platform

Posted on 18 March 2010 by Ask-Cato.com Contributor

Although cancer immunotherapeutics (intended to treat already existing cancers by strengthening the body’s natural defenses) represent a very active area of development world wide, few cancer immunotherapeutics have been approved to date. Unfortunately, the overall clinical benefit in patients treated … Continue reading →

Posted in Clinical Trials | Tagged , , , , | Comments Off